Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Arnott(Medway Maritime Hospital), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Michael A. Chapman(Toronto Metropolitan University), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Sally Moore(University College Hospital), Reuben Benjamin(King's College Hospital), Selina J Chavda(University College London), Andres Virchis(The Royal Free Hospital), Sandra Hassan(Queen's Hospital), Jamie Cavenagh(St Bartholomew's Hospital), Ruth M. de Tute(St James's University Hospital), Fenella Willis(St George's Hospital), William Wilson(Cancer Research UK)
Cited by 8
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719